Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/38765
Title: Efficacy of predictive models for polycystic ovary syndrome using serum levels of two antimullerian hormone isoforms (proAMH and AMHN,C).
Authors: Rodgers R.J.;Moran L.J.;Pankhurst M.W.;Shorakae S.;Teede H.J. 
Institution: (Pankhurst) Department of Anatomy, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand (Rodgers, Moran) The Robinson Research Institute, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia (Shorakae, Teede, Moran) Monash Centre for Health Research Implementation, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (Shorakae, Teede) Diabetes and Vascular Medicine Unit, Monash Health, Melbourne, Victoria, Australia
Issue Date: 14-Nov-2017
Copyright year: 2017
Publisher: Elsevier Inc. (E-mail: usjcs@elsevier.com)
Place of publication: United States
Publication information: Fertility and Sterility. 108 (5) (pp 851-857.e2), 2017. Date of Publication: November 2017.
Journal: Fertility and Sterility
Abstract: Objective To compare total antimullerian hormone (AMH), proAMH, AMHN,C, and the ratio of the two forms in predictive models for polycystic ovary syndrome (PCOS) diagnosis. Total AMH consists of proAMH (inactive precursor) and AMHN,C (receptor-competent), but neither isoform has been tested individually for their ability to predict PCOS diagnosis. Design Cross-sectional study using biobanked samples collected between July 2008 and January 2010. Setting Not applicable. Patient(s) Overweight, premenopausal women aged 18-45 years with PCOS (n = 45, with 21 fulfilling National Institutes of Health diagnostic criteria and 24 fulfilling European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE) criteria, but not National Institutes of Health criteria) and without PCOS (n = 23 controls). Intervention(s) None. Main Outcome Measure(s) Serum concentrations of proAMH and total AMH (proAMH and AMHN,C combined) were determined by immunoassay. The AMHN,C concentrations were calculated by subtraction ([AMHN,C] = [total AMH] - [proAMH]). Relative levels of proAMH were expressed as the AMH prohormone index (API = [ProAMH]/[Total AMH] x 100). Result(s) In women with PCOS, total AMH, proAMH, and AMHN,C levels were higher, and the API was lower (P=.010), than in controls indicating increased conversion of proAMH to AMHN,C. Receiver-operating characteristic analysis for proAMH (area under the curve [AUC] = 0.82), AMHN,C (AUC = 0.86), and API (AUC = 0.70) did not improve the prediction for PCOS when compared with total AMH (AUC = 0.86). Conclusion(s) The proAMH and AMHN,C do not appear to improve the ability to predict a diagnosis of PCOS beyond total AMH assays. However, the ratio of inactive proAMH precursor to receptor-competent AMHN,C (API) differs in women with PCOS relative to unaffected controls indicating that AMH signaling mechanisms may be altered in women with PCOS.Copyright © 2017 American Society for Reproductive Medicine
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.fertnstert.2017.08.012
PubMed URL: 29079276 [http://www.ncbi.nlm.nih.gov/pubmed/?term=29079276]
ISSN: 0015-0282
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/38765
Type: Article
Type of Clinical Study or Trial: Observational study (cohort, case-control, cross sectional or survey)
Appears in Collections:Articles

Show full item record

Page view(s)

14
checked on Nov 4, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.